A judge at France's top administrative court, the Conseil d'Etat, has denied a request from Roche to suspend the government's decision to reimburse its anticancer, Avastin (bevacizumab), for the off-label indication of wet age-related macular degeneration (AMD)1.
The Swiss firm had asked the court to suspend the temporary use recommendation (Recommandation Temporaire d'Utilisation, or RTU) allowing Avastin's...




